| PDIA6 Protein | |
|---|---|
| Protein Name | PDIA6 Protein |
| Gene Symbol | PDIA6 |
| UniProt ID | Q15020 |
| PDB Structures | 3U1G, 3U1H |
| Molecular Weight | 48 kDa |
| Subcellular Localization | Endoplasmic Reticulum Lumen |
| Protein Family | Protein Disulfide Isomerase Family |
PDIA6 is a protein involved in protein folding and ER homeostasis.[1] This protein plays important roles in the endoplasmic reticulum where it assists in protein folding and quality control.[2] In the context of neurodegenerative diseases, PDIA6 is implicated in Alzheimer's disease, Parkinson's disease, and other disorders through various mechanisms.[3]
PDIA6 has a distinct structure compared to classical PDIs. It contains two thioredoxin-like domains but lacks the classical C-terminal active site motif. The protein has a flexible structure allowing it to interact with various client proteins. PDIA6 can form complexes with other ER chaperones and has a KDEL retrieval sequence for ER retention.
PDIA6 functions as an ER chaperone and assists in protein folding. Unlike classical PDIs, it has less specific disulfide isomerase activity and acts more as a molecular chaperone. PDIA6 is involved in the unfolded protein response (UPR) and helps manage ER stress. It has anti-apoptotic properties and can protect cells from ER stress-induced cell death. PDIA6 can also translocate to other cellular compartments under certain conditions.
PDIA6 is implicated in neurodegenerative diseases through its role in ER homeostasis. In Alzheimer's disease, PDIA6 expression is altered in response to amyloid pathology and helps manage misfolded protein stress. In Parkinson's disease, PDIA6 may assist in clearing alpha-synuclein. Reduced PDIA6 function contributes to ER stress-mediated neuronal death. The protein is being studied as a potential biomarker for neurodegenerative diseases.
Enhancing PDIA6 function through pharmacological approaches may help treat neurodegenerative diseases by improving ER protein folding capacity. However, specific PDIA6 modulators are not well developed. Gene therapy approaches to increase PDIA6 expression are being explored. The protein represents a potential therapeutic target for enhancing cellular protein quality control mechanisms.